WilmerHale Advises Millennium Pharmaceuticals in $8.8 Billion Acquisition by Takeda

Download IconDownload Print IconPrint

WilmerHale Advises Millennium Pharmaceuticals in $8.8 Billion Acquisition by Takeda

Firm News

Related Solutions

With a team of lawyers recognized nationally as leading practitioners in the field, we regularly advise public and private companies, their shareholders and their key employees on tax aspects of mergers, acquisitions, dispositions and joint ventures. Clients rely on our advice to maximize their tax efficiencies and minimize their tax risks. Our clients include businesses from a wide range of sectors: technology, life sciences, publishing, telecommunications, aviation and defense, venture capital and private equity. We develop tax-efficient structures that help clients achieve business objectives and negotiate appropriate contractual protections against the assumption of unwanted tax risks.
A deep and diverse practice focused on maximizing tax efficiencies and minimizing tax risks for clients nationally and internationally.
“The firm is at its best during a fight—whether that’s against an enforcer, or in court against a private litigant.” — Global Competition Review
A global team handling highly complex and sensitive matters in all aspects of litigation.
We offer clients exceptional insight in dealing with competition agencies in the United States, Europe and around the world.
A team of WilmerHale lawyers advised Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) in connection with its proposed $8.8 billion acquisition by Takeda Pharmaceutical Company Limited (TSE: 4502) through a cash tender offer. The deal is the largest overseas acquisition by a Japanese drug manufacturer.

Serving as Millennium’s M&A counsel in the transaction are WilmerHale lawyers David Redlick, Hal Leibowitz, Jeffrey Hermanson, Brian Johnson, Emily Babalas, Jason Kropp and Sonia Bednarowski. The M&A team is assisted by antitrust partners William Kolasky and Sven Voeckler, and tax partners William Schmidt and Robert Burke.

WilmerHale has served as primary outside counsel to Millennium since the early 1990s. Millennium is a leading biopharmaceutical company based in Cambridge, Massachusetts that markets VELCADE, a novel cancer product, and has oncology and inflammation product candidates in various stages of development.

Click here for Millennium Pharmaceutical’s complete press release.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel